ClinicalTrials.gg

Program

turmetabart adizutecan

In AbbVie’s pipeline, SEZ6. Its studies are mostly in Small Cell Lung Carcinoma · Neoplasms, led by AbbVie.

Furthest: phase 3, since Jan 22, 20265 company-led studies, 5 open or runningNext primary completion: Nov 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie55 open or runningphase 3since Jan 22, 2026Oct 28, 2022Nov 2027phase 1 · NCT05599984
  • Named in AbbVie’s own pipeline as ABBV-706, phase 3, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 28, 2022First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT05599984 · 288 enrolled · United States, Australia, China and more
  2. Aug 28, 2025Phase 2 study in Small Cell Lung CarcinomaNCT07155174 · 180 planned · United States, Belgium, China and more
  3. Jan 22, 2026Phase 3 study in Small Cell Lung CarcinomaPhase 3 reachedNCT07365241 · 531 planned · United States, Austria, Belgium and more
  4. Oct 20, 20262 phase 2 studies in NeoplasmsNCT07895056, NCT07895043

Ahead

  1. Nov 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT05599984
  2. Apr 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT07155174
  3. Sep 2030Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07365241
  4. Aug 2031Primary completion: phase 2 study in NeoplasmsNCT07895056

TargetBeta

“SEZ6”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of turmetabart, a monoclonal antibody directed against seizure protein 6 homolog (SEZ6), ”NCIt, by rule

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07895056Neoplasms2Not yet recruitingAug 203180
NCT07895043Neoplasms2Not yet recruitingDec 203180
NCT07365241Small Cell Lung Carcinoma · United States, Austria, Belgium and more3RecruitingSep 2030531
NCT07155174Small Cell Lung Carcinoma · United States, Belgium, China and more2RecruitingApr 2029180
NCT05599984Small Cell Lung Carcinoma · United States, Australia, China and more1Active, not recruitingNov 2027288

How it is read

Names in the registry

  • “ABBV-706”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.